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Gregory L. Moneta, MD, Section EditorTobacco Control and the Reduction in Smoking-Related Premature
Deaths in the United States, 1964-2012
Holford TR, Meza R, Warner KE, et al. JAMA 2014;311:164-71.
Conclusions: In the United States, tobacco control is estimated to
have been associated with avoidance of 8 million premature deaths and an
estimated extension of mean life span of 19 to 20 years.
Summary: January 2014 marked the 50th anniversary of the ﬁrst
Surgeon General’s report on smoking and health (Surgeon General’s
Advisory Committee on Smoking and Health [1964] http://proﬁles.
nlm.nih.gov/NN/B/B/M/Q/, accessed December 13, 2013.) What
followed were efforts by governments, voluntary organizations, and
the private sector to provide education on smoking dangers. Also fol-
lowed were increases in cigarette taxes, smoke-free air laws, antismoking
media campaigns, marketing and sales restrictions on tobacco com-
panies, lawsuits, and a greater focus on smoking-cessation treatment
programs. A recent report also estimates many individuals in the United
States gained additional years of life from 1964 through 2012, with this
a direct result of tobacco control-inﬂuenced decisions to quit smoking
or never start smoking (Warner KE et al, Am J Public Health
2014;104:83-9). It is also estimated that >800,000 lung cancer deaths
have been avoided between 1975 and 2000 as a result of tobacco control
(Moolgavkar SH et al, J Natl Cancer Inst 2012;104:541-8). The objec-
tive of this current report was to model reductions in smoking-related
mortality associated with implementation of tobacco controls since
1964. Smoking histories for individual birth cohorts that would have
occurred under likely scenarios had tobacco control never emerged
were estimated. National mortality rates and mortality rate ratio esti-
mates from analytic studies of the effect of smoking on mortality yielded
death rates by smoking status. Actual smoking-related mortality from
1964 through 2012 was compared with estimated mortality under no
tobacco control, including a likely scenario (primary counterfactual)
and upper and lower bounds that would capture plausible alternatives.
Smoking histories were obtained from National Health Interview Sur-
veys for the United States adult population from 1964 through 2012.
The number of premature deaths avoided and years of life saved were
primary outcomes. Change in life expectancy at age 40 years associated
with change in cigarette smoking exposure constituted another measure
of overall health outcome. From 1964 to 2012, an estimated 17.7
million deaths were related to smoking. An estimated 8.0 million (cred-
ible range [CR], 7.4-8.3, million for the lower and upper tobacco con-
trol counterfactuals, respectively) fewer premature smoking-related
deaths than what would have occurred under the alternatives and thus
associated with tobacco control (5.3 [CR, 4.8-5.5] million men and
2.7 [CR, 2.5-2.7] million women). This resulted in an estimated 157
million life-years (CR, 139-165 million life-years) saved, a mean of
19.6 years for each beneﬁciary (111 [CR, 97-117] million life-years
for men, 46 [CR, 42-48 ] million life-years for women). During this
time, estimated life expectancy at age 40 increased 7.8 years for men
and 5.4 years for women, of which tobacco control is associated with
2.3 years (CR, 1.8-2.5 years) for men (30% [CR, 23%-32%] of the in-
crease) and 1.6 years (CR, 1.4-1.7 years) for women (29% [CR, 25%-
32%] of the increase).
Comment: Since the Surgeon General Report of 1964 and the
implementation of tobacco controls, the fact that an estimated 8 million
U.S. individuals have had their lives extended by these tobacco controls
argues that tobacco control has in a sense been a great public health suc-
cess story. Unfortunately, however, nearly 50 years later, still a ﬁfth of
U.S. adults continue to smoke, and smoking continues to claim hun-
dreds of thousands of lives annually. In fact, an additional article in
the same issue of the Journal of the American Medical Association, in
which this article appeared, indicates that since 1980, although there
have been large reductions in the estimated percentage prevalence of
daily smoking globally for men and women, population growth means
the actual number of smokers has in fact increased signiﬁcantly. Tobacco
therefore still remains a threat, and perhaps a potentially increasing
threat, to the health of the world’s population (Ng M et al, JAMA
2014;311:183-92).1174A Clinical Rule (Sex, Contralateral Occlusion, Age, and Restenosis)
to Select Patients for Stenting Versus Carotid Endarterectomy:
Systematic Review of Observational Studies With Validation in
Randomized Trials
Touzé E, Trinquart L, Felgueiras R, et al. Stroke 2013;44:3394-400.
Conclusions: A clinical prediction rule based on sex, contralateral ca-
rotid occlusion, age, and restenosis may be potentially useful in identifying
patients in whom carotid artery stenting (CAS) is not inferior with respect to
carotid endarterectomy (CEA) for risk of perioperative stroke or death.
Summary: Randomized trials strongly suggest CAS is associated with
higher procedural risk of stroke than CEA in patients with symptomatic ste-
nosis (Bonati LH et al, Cochrane Database Syst Rev 2012;9:CD000515;
and Brott TG et al, N Engl J Med 2010;363:11-23). However, additional
data suggest that risk of stroke may be similar for CAS and CEA after the
periprocedural period (Mas JL et al, Lancet Neurol 2008;7:885-92; and
Eckstein HH et al, Lancet Neurol 2008;7:893-902). The authors of the
current report have also previously demonstrated that meta-analysis of risk
associations from a compilation of large observational studies can provide
potentially reliable and consistent data on clinical characteristics associated
with procedural risk of CEA and CAS (Bonati LH et al, Lancet
2010;376:1062-73). In this study, the authors sought to derive a simple
clinical risk rule to enable clinicians to potentially choose between CAS
and CEA in the treatment of patients with symptomatic carotid artery ste-
nosis. This was a systematic review of observational studies of procedural
risk of CEA or CAS, which extracted data on nine predeﬁned risk factors:
age, contralateral carotid occlusion, coronary artery disease, diabetes melli-
tus, sex, hypertension, peripheral artery disease, and type and side of steno-
sis. Pooled relative risks of procedural stroke or death were then calculated.
Factors with differential effects on the risk of CAS vs CEA were identiﬁed by
interaction tests and used to derive a rule for patient selection. The rule was
then tested using individual patient data from randomized trials of CAS vs
CEA from The Carotid Stenting Trialists’ Collaboration.
The authors identiﬁed 170 studies for inclusion in their analysis. Two
independent reviewers used titles and abstracts to assess the eligibility of
studies. Final selection for inclusion in the analysis was made after reviewing
full-text articles. Ultimately, 170 studies (227 articles, >70,000 patients)
provided data for one or more of the nine potential risk factors. There
were 115 studies (149 articles) relating to CEA and 68 studies (83 articles)
relating to CAS, with some studies related to both CEA and CAS. Analysis
indicated patients with contralateral occlusion or restenosis and women
aged <75 years were at relatively low risk for CAS (SCAR-negative), with
all others being high risk (SCAR-positive). In the Carotid Stenting Trialists’
Collaboration validation portion of the study, there were 3049 patients, and
694 (23%) were SCAR-negative. The pooled relative risk of procedural
stroke and death with CAS vs CEA was 0.93 (0.49-1.77; P ¼ .83) in
SCAR-negative patients and 2.41 (1.68-3.45; P < .0001) in SCAR-positive
patients (P ¼ .05 for interaction).
Comment: The data have several limitations. First, most patients with
recurrent carotid stenosis likely do not need treatment. In addition, the au-
thors were not able to stratify for type of protection devices used with CAS,
and data were not available concerning anatomic variables, such as type of
aortic arch, angulation of the carotid artery, severe calciﬁcation of the ca-
rotid bifurcation, or plaque composition, that may have signiﬁcant inﬂuence
on periprocedural risk of CAS. From a simplistic point of view, one can
make the observation that there was no score that indicated CAS was better
than CEA and that the large majority of patients were best treated with CEA
over CAS based on the clinical score derived. It therefore appears, as we
already knew, that in the large majority of clinical circumstances, CEA still
seems preferable to CAS.
A Pragmatic View of the New Cholesterol Treatment Guidelines
Keaney JF, Curfman GD, Jarcho JA. N Engl J Med 2014;370:275-8.
Conclusions: The new cholesterol treatment guidelines represent a
substantial departure from previous recommendations.
Summary: This short article summarized updated guidelines for the
treatment of high blood cholesterol levels that were released in November
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(ACC-AHA) Task Force on Practice Guidelines (Stone NJ et al, Circulation
2013 [E-pub ahead of print] doi: 10.1161/01.cir.0000437738.63853.7a).
These new guidelines represent a signiﬁcant departure from previous recom-
mendations that promoted speciﬁc lipid-level goals for patients that
depended on level of risk. The new guidelines rely heavily on randomized,
controlled trials involving ﬁxed doses of statin medications in patients at risk
for atherosclerotic cardiovascular disease. Four subgroups of patients were
identiﬁed where beneﬁts of statins outweigh risk. These included (1) those
with clinically evident atherosclerotic cardiovascular disease; (2) primary
low-density lipoprotein (LDL) cholesterol levels $190 mg/dL; (3) patients
with type 1 or type 2 diabetes and LDL cholesterol levels $70 mg/dL; and
(4) patients with a 10-year risk of atherosclerotic cardiovascular disease of at
least 7.5% and an LDL cholesterol level $70 mg/dL. In addition, the new
guidelines identify patients for whom data do not support statin therapy.
These include those aged$75 years unless clinical atherosclerotic cardiovas-
cular disease is present, those with a need for hemodialysis, or patients with
New York Heart Association class II, III, or IV heart failure. In addition, the
panel noted that there was no evidence to support use of nonstatin choles-
terol-lowering drugs combined with statin therapy or in statin-intolerant
patients.
Comment: Adherence to the new guidelines will result in consider-
able changes in practice patterns that include avoidance of cholesterol-
lowering therapy in certain patient groups and elimination of routine
assessments of LDL cholesterol levels in patients receiving statin therapy
because target levels are no longer emphasized. Additional changes
include avoidance of nonstatin LDL cholesterol-lowering agents, more
conservative use of statins in patients aged >75 years, and diminished
use of surrogate markers, such as C-reactive protein or calcium scores,
for selection of patients for statin therapy. Finally, the use of a new risk
calculator in the new guidelines is likely to target larger numbers of
patients for statin therapy.
Screening for Peripheral Artery Disease and Cardiovascular Disease
Risk Assessment With the Ankle-Brachial Index in Adults: U.S.
Preventive Services Task Force Recommendation Statement
Moyer VA, and the U.S. Preventive Services Task Force. Ann Intern Med
2013; 159:342-8.
Conclusions: Current evidence is insufﬁcient to assess the balance of
beneﬁts and harms for screening for peripheral arterial disease (PAD) and
cardiovascular disease (CVD) risk assessment with ankle-brachial index
(ABI) in adults.
Summary: The U.S. Preventive Services Task Force (USPSTF) makes
recommendations about effectiveness of speciﬁc preventive care services for
patients without disease-related symptoms. Recommendations are based on
balance of beneﬁts and harm of the potential testing modality with respect
to the disease process undergoing evaluation. With respect to PAD, early
detection of PAD in asymptomatic patients is primarily considered because
subsequent treatment may reduce overall CVD. However, the USPSTF
found no evidence that screening for treatment of PAD in asymptomatic pa-
tients can provide clinically important beneﬁts. In fact, one randomized trial
found that aspirin did not reduce CVD events in patients with low ABI
(Fowkes FG et al, JAMA 2010;303:841-8). The same trial found that
low-dose aspirin treatment in asymptomatic patients with a low ABI might
actually increase bleeding. Additional harms considered by the USPSTF for
screening ABI included false-positive results, with the potential of subse-
quent exposure to gadolinium or a contrast agent if additional studies are
used to conﬁrm diagnoses. In addition, patient anxiety and opportunity
costs were also considered potential harms. Additional potential harms
included the use of unnecessary medications (or higher doses) and the
resulting adverse effects of additional medications or increased medication
dosages. Most of these potential harms are downstream harms because there
is little potential harm associated with conducting the ABI examination it-
self. This study follows two previous recommendations by the USPSTF
against screening for PAD, the ﬁrst in 1996 and the second in 2005. The
current study focused on broader CVD outcomes than previous reviews
and speciﬁcally focused on resting ABI as the sole screening method.
Although the USPSTF found evidence that ABI is a reliable screening
test for PAD, the ultimate conclusion was that the evidence to support treat-
ment based on this screening test is inadequate and that there were no
studies addressing harms of screening.
Comment: Detection of asymptomatic peripheral arterial disease may
identify patients at risk for other types of CVD other than just PAD. How-
ever, evidence directly supporting this supposition is lacking. “Therefore the
USFPSTF concludes that the evidence on the balance of beneﬁts and harms
of screening is lacking.” One must also consider that many patients with
asymptomatic low ABIs may never develop clinical signs or symptoms of
CVD and yet if treated on the basis of the low ABI would be subject tothe harms of testing and subsequent treatments. With the exception of
screening for abdominal aortic aneurysm, screening for any form of PVD
remains controversial.
Carotid Plaque MRI and Stroke Risk: A Systematic Review and Meta-
analysis
Gupta A, Baradaran H, Schweitzer AD, et al. Stroke 2013;44:3071-7.
Conclusions: Dedicated magnetic resonance imaging (MRI) of pla-
que composition offers stroke risk information beyond measurement of
luminal stenosis in carotid atherosclerotic disease.
Summary: Stenosis severity is widely used as a marker for stroke risk
in patients with atherosclerotic carotid disease. However, evidence also sug-
gests plaque composition can also predict stroke risk independent of stenosis
severity (den Hartog AG et al, Eur J Vasc Endovasc Surg 2013;45:7-21).
MRI measurements of plaque composition may help characterize carotid
plaques with respect to stroke risk. However, individual studies have been
relatively small, and it is unclear whether differences in risk proﬁles of spe-
ciﬁc plaque components, such as intraplaque hemorrhage, lipid-rich necrotic
core, or thinning/rupture of the ﬁbrous cap, contribute differentially to
stroke risk. The authors therefore performed a systematic review and
meta-analysis to evaluate whether MRI of plaque composition is a predictor
of ipsilateral ischemic stroke or transient ischemic attack (TIA) in carotid
atherosclerotic disease. A comprehensive literature search evaluated the as-
sociation of carotid plaque composition on MRI with ischemic outcomes.
Included studies were cohort studies examining intraplaque hemorrhage,
lipid-rich necrotic core, or thinning/rupture of the ﬁbrous cap with a
mean follow-up of $1 month and an outcome measure of ipsilateral stroke
or TIA. A meta-analysis using a random-effects model assessing study het-
erogeneity and publication biases was performed. The authors screened
3436 articles, and nine studies with a total of 779 subjects met eligibility
for systematic review. Ratios for intraplaque hemorrhage, lipid-rich necrotic
core, and thinning/rupture of the ﬁbrous cap as predictors of subsequent
stroke/TIA were 4.59 (95% conﬁdence interval [CI], 2.91-7.24), 3.00
(95% CI, 1.51-5.95), and 5.93 (95% CI, 2.65-13.20), respectively. There
was no signiﬁcant heterogeneity or publication bias in the three main
meta-analyses performed.
Comment: One possible conclusion of this article, given the number
of articles potentially available for inclusion in this study and the small num-
ber subsequently selected for systematic review, is that there must be
remarkable limitations of the current literature on MRI plaque characteriza-
tion. Therefore, the use of carotid plaque MRI to select high-risk groups
potentially beneﬁting from carotid intervention remains quite problematic
at this point. The study does point out that the MRI variables of intraplaque
hemorrhage, lipid-rich necrotic core, and thinning of the ﬁbrous cap are tar-
gets for future research.
Doxycycline for Stabilization of Abdominal Aortic Aneurysms: A
Randomized Trial
Meijer CA, Stigmen T, and the Pharmaceutical Aneurysm Stabilization Trial
Study Group. Ann Intern Med. 2013;159:815-23.
Conclusions: Doxycycline therapy for 18 months does not reduce
aneurysm growth and does not inﬂuence need for aneurysm repair or
time to repair.
Summary: Matrix metalloproteinases (MMPs) appear to be involved
in abdominal aortic aneurysm (AAA) pathogenesis and pathophysiology.
Doxycycline is a nonspeciﬁc MMP inhibitor and has been shown to decrease
AAA formation and progression in preclinical models of aneurysm disease
(Bergqvist D, Eur J Vasc Endovasc Surg 2011;41:663-7; and Dodd BR
et al, Curr Vasc Pharmacol 2011;9:4-8). In addition, a small study of 3
months of doxycycline reported reduced aneurysm growth 6 to 12 months
later (Mosorin M et al, J Vasc Surg 2001;34:6-10). Finally, a safety trial of
6 months of doxycycline treatment reported that “the observed rate of
aneurysm growth compared favorably with that described in natural history
studies of aneurysm growth” (Baxter BT et al, J Vasc Surg 2002;36:1-12).
Other medical therapies, most prominently b-blockers, have been consid-
ered for medical management of disease but have not been conclusively
demonstrated to reduce progression of AAAs. Currently, doxycycline is
considered to be the lead candidate for potential pharmaceutical stabiliza-
tion of AAAs. The purpose of this study was to test whether doxycycline
inhibits AAA progression in humans. This was a randomized placebo-
controlled, double-blind trial conducted in 14 Dutch hospitals. The study
recruited 286 patients with small AAAs and randomized 144 to daily doses
of 100 mg doxycycline and 142 to placebo for 18 months. The two groups
were well balanced with respect to baseline demographic and clinical char-
acteristics. The primary outcome measure was aneurysm growth at 18
months, as estimated by repeated single-observer ultrasound study. Second-
ary outcome measures included aneurysm growth at 12 months and need
